CAR T Cells: Second-Line Treatment Option for NHL? - NCI

Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.

Driving the next wave of innovation in CAR T-cell therapies

Frontiers The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma, Experimental Hematology & Oncology

CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? - ScienceDirect

Fertility and CAR T-cells: Current practice and future directions - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy

Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy - Biology of Blood and Marrow Transplantation

Non-Hodgkin's Chemotherapy, Radiation, & Immunotherapy Treatments

Chimeric antigen receptor T-cell therapies for lymphoma

CAR T Cells: Second-Line Treatment Option for NHL? - NCI

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy - Transplantation and Cellular Therapy, Official

Clinical responses to the two kinds of CAR-T cell therapy. (A).

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI

The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study

Frontiers CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure